News
Market and company headlines
GUTSAll
Loading
03:00-08:00Oct 222 Stories
Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance
Following positive topline six-month REMAIN-1 pivotal results, Revita advancing toward planned FDA De Novo submission in late Q4 2026 and anticipated 12-month pivotal data readout in Q1 2027 Workforce reduction aligns organization behind Revita's near-term clinical and commercial opportunity Company discontinuing development of Rejuva candidates and seeking strategic alternatives to maximize the value of its Rejuva gene therapy program Cash runway extended into Q2 2027; quarterly operating cash
Fractyl Health Announces Heightened Focus On Advancing Revita Toward Potential FDA Marketing Authorization And Commercialization In Post-GLP-1 Weight Maintenance
Following positive topline six-month REMAIN-1 pivotal results, Revita advancing toward planned FDA De Novo submission in late Q4 2026 and anticipated 12-month pivotal data readout in Q1 2027Workforce reduction aligns
07:00Oct 201 Story
10:00-14:00Oct 192 Stories
Unusual Volume Standouts in the Latest Session
Stocks trading well above their 50-day average volume include MNDR, NWGL, XXII, TCRT, SKYA, SHFS, GUTS, WFF, HUBC and DKI, with sharp price moves.
Morgan Stanley Maintains Equal-Weight on Fractyl Health, Lowers Price Target to $4
Morgan Stanley analyst Michael Ulz maintains Fractyl Health (NASDAQ:GUTS) with a Equal-Weight and lowers the price target from $24 to $4.
12:00-14:00Oct 162 Stories
Fractyl Health, Inc. (GUTS) Discusses Positive Top Line 6-Month Results From REMAIN-1 Study of Revita in Post GLP-1 Weight Maintenance Transcript
Fractyl Health, Inc. (GUTS) Discusses Positive Top Line 6-Month Results From REMAIN-1 Study of Revita in Post GLP-1 Weight Maintenance October 16, 2026 8:00...
Top US Stock Gainers and Losers in Today's Session
See today's largest US stock movers, including OPENW up 56.63%, MDXH down 60.55%, and other notable gainers and losers from the session.
08:00-10:00Oct 162 Stories
Fractyl Health Meets Six-Month Primary Endpoint in Revita Obesity Trial, Supporting FDA Submission Plans
Fractyl Health reports statistically significant reductions in weight regain following GLP-1 discontinuation, advancing its Revita treatment toward a potential FDA submission in late 2026. Key Investor TakeawaysFractyl Health (NASDAQ:GUTS) met the six-month co-primary endpoint in its 308-participant REMAIN-1 pivotal study, demonstrating a statistically significant reduction in weight regain (p=0.
Fractyl Health, Inc. (GUTS) Discusses Positive Top Line 6-Month Results From REMAIN-1 Study of Revita in Post GLP-1 Weight Maintenance - Slideshow
2026-10-16. The following slide deck was published by Fractyl Health, Inc.
06:00-08:00Oct 162 Stories
Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation
REMAIN-1 met its six-month co-primary endpoint with high statistical significance (p=0.0023; mITT population); demonstrated 80% retention of GLP-1 induced weight loss vs 67% for sham 32% of Revita® participants in primary analysis population (mITT) were either weight stable or had further weight loss at 6-months post GLP-1 discontinuation vs 18% for sham (post hoc; nominal p=0.020) Post hoc analyses demonstrated that patients receiving a single complete duodenal ablation with Revita (>=20 cm len
Why Fractyl Health Stock Is Sinking Friday
Fractyl Health (GUTS) stock sank 50% despite positive REMAIN-1 trial results as class action lawsuit concerns weigh on investors.
03:00Oct 161 Story
17:00Oct 11 Story
16:00Sep 141 Story
07:00Sep 91 Story
12:00-00:00Aug 102 Stories
Fractyl Health, Inc. (GUTS) Q2 2026 Earnings Call Transcript
Fractyl Health, Inc. (GUTS) Q2 2026 Earnings Call August 10, 2026 4:30 PM EDTCompany ParticipantsBrian Luque - Head of Investor Relations & Corporate...
Fractyl Health Q2 EPS $(0.16) Misses $(0.13) Estimate
Fractyl Health (NASDAQ:GUTS) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 71.93 percent increase over losses of $(0.57) per share from